15 patents
Utility
Cardiovascular Event Risk Prediction
7 Dec 23
Biomarkers, methods, devices, reagents, systems, and kits used to assess an individual having heart failure with preserved ejection fraction (HFpEF) or having heart failure with reduced ejection fraction (HFrEF) for the prediction of risk of developing a Cardiovascular (CV) Event over a 90 day, 180 day, or 1 year period are provided.
Laura Mae Sampson, Michael Albert Hinterberg, Yi Jia, Rachel Marie Ostroff, Yolanda Hagar
Filed: 19 Oct 21
Utility
Proteomic Assay Using Quantum Sensors
2 Nov 23
Apparatus and methods for the detection of proteins in biological fluids such as urine using a label-free assay is described.
Jason Paul CLEVELAND, Karoly HOLCZER, Barry Patrick John VANT-HULL
Filed: 11 Jul 23
Utility
Oligonucleotides Comprising Modified Nucleosides
5 Oct 23
Polynucleotides, such as aptamers, comprising at least first one 5-position modified pyrimidine and at least one second 5-position modified pyrimidine are provided, wherein the first and second 5-position modified pyrimidines are different.
Jeff Carter, Bharat Gawande, Nebojsa Janjic, Daniel Schneider
Filed: 12 Jan 23
Utility
Proteomic assay using quantum sensors
11 Jul 23
Apparatus and methods for the detection of proteins in biological fluids such as urine using a label-free assay is described.
Jason Paul Cleveland, Karoly Holczer, Barry Patrick John Vant-Hull
Filed: 15 Feb 22
Utility
Next-generation Sequencing for Protein Measurement
6 Jul 23
Methods of detecting and quantifying target molecules, such as proteins, in a biological sample are provided.
Dom ZICHI, Allison WEISS, David SEGHETTI, Kathryn JENKO
Filed: 29 Dec 22
Utility
Nucleic Acid Compounds for Binding to Complement Component 3 Protein
23 Mar 23
Described herein are aptamers capable of binding to human complement component 3 (C3) protein; compositions comprising a C3 binding aptamer with a C3-Protein; and methods of making and using the same.
Daniel W. Drolet, Chi Zhang, Daniel J. O'Connell, Shashi Gupta
Filed: 29 Aug 22
Utility
Nonalcoholic Steatohepatitis (NASH) Biomarkers and Uses Thereof
9 Mar 23
Methods, compositions, and kits for determining whether a subject has a liver condition, including hepatic steatosis, hepatic inflammation, hepatocellular ballooning, and/or hepatic fibrosis, are provided.
Leigh Alexander, Rachel Ostroff, Stuart G. Field
Filed: 9 Feb 21
Utility
Methods of Determining Impaired Glucose Tolerance
16 Feb 23
Methods, compositions, and kits for determining whether a subject has impaired glucose tolerance, and more specifically pre-diabetes or diabetes, are provided.
Yolanda Hagar
Filed: 8 Jan 21
Utility
Oligonucleotides comprising modified nucleosides
14 Feb 23
Polynucleotides, such as aptamers, comprising at least first one 5-position modified pyrimidine and at least one second 5-position modified pyrimidine are provided, wherein the first and second 5-position modified pyrimidines are different.
Jeff Carter, Bharat Gawande, Nebojsa Janjic, Daniel Schneider
Filed: 18 Dec 20
Utility
Nucleic acid compounds for binding growth differentiation factor 11
27 Dec 22
Described herein are aptamers capable of binding to growth differentiation factor 11 (GDF11) protein; compositions comprising a GDF11 binding aptamer with a GDF11 protein; and methods of making and using the same.
Urs Ochsner, Louis Green, Dom Zichi, Nebojsa Janjic
Filed: 16 Sep 20
Utility
Cardiovascular Risk Event Prediction and Uses Thereof
3 Nov 22
Biomarkers, methods, devices, reagents, systems, and kits used to assess an individual for the prediction of risk of developing a primary or secondary Cardiovascular (CV) event over a 4 year period are provided.
Michael Hinterberg, Gargi Datta
Filed: 2 Sep 20
Utility
Nucleic Acid Compounds that Bind to Retinoic Acid-Inducible Gene I Protein
20 Oct 22
Described herein are aptamers capable of binding to human retinoic acid-inducible gene I protein (RIG-I); compositions comprising a RIG-I binding aptamer with a RIG-I; and methods of making and using the same.
Nebojsa Janjic, Amy Gelinas
Filed: 15 Oct 20
Utility
Nucleic acid compounds for binding to complement component 3 protein
11 Oct 22
Described herein are aptamers capable of binding to human complement component 3 (C3) protein; compositions comprising a C3 binding aptamer with a C3-Protein; and methods of making and using the same.
Daniel W. Drolet, Chi Zhang, Daniel J. O'Connell, Shashi Gupta
Filed: 29 May 15
Utility
Method, Apparatus, and Computer-readable Medium for Adaptive Normalization of Analyte Levels
15 Sep 22
A method, apparatus, and computer-readable medium for adaptive normalization of analyte levels in one or more samples, the method including receiving one or more analyte levels corresponding to one or more analytes detected in the one or more samples, each analyte level corresponding to a detected quantity of that analyte in the one or more samples; and iteratively applying a scale factor to the one or more analyte levels over one or more iterations until a change in the scale factor between consecutive iterations is less than or equal to a predetermined change threshold or until a quantity of the one or more iterations exceeds a maximum iteration value, each iteration in the one or more iterations comprising: determining a distance between each analyte level in the one or more analyte levels and a corresponding reference distribution of that analyte in a reference data set; determining the scale factor based at least in part on analyte levels that are within a predetermined distance of their corresponding reference distributions; and normalizing the one or more analyte levels by applying the scale factor.
Eduardo Daniel Tabacman, Dominic Anthony Zichi, Matthew Joel Westacott, Darryl Jon Perry
Filed: 24 Jul 20
Utility
Controlling Intersample Analyte Variability in Complex Biological Matrices
18 Aug 22
Described herein are compositions and methods for normalizing the variability of inter-sample analyte measurements from a biological matrix.
Thomas Hraha
Filed: 15 May 20
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first